Day: June 18, 2024

FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) — Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma...

VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) — Christina Lake Cannabis Corp. (“CLC” or the “Company”) (CSE: CLC) is pleased to confirm that further to its news releases dated April 3, 2024, April 17, 2024, May 1, 2024, May 15, 2024, May 29, 2024 and June 3, 2024, the Company has filed on SEDAR its audited financial statements, accompanying management discussion and analysis and related CEO and CFO certifications for the year ended November 30, 2023 (the “Annual Filings”). The Annual Filings can be obtained on the Company’s SEDAR profile at www.sedarplus.ca. As a consequence of the Annual Filings, the Company expects that the management cease trade order formerly granted on April 3, 2024, by applicable securities regulatory authorities, will be revoked and that directors and...

BOUCHERVILLE, Québec, June 18, 2024 (GLOBE NEWSWIRE) — LSL PHARMA GROUP INC. (TSXV: LSL) (“the Company” or “LSL Pharma”), a Canadian integrated pharmaceutical company, is pleased to announce the completion of the acquisition of Virage Santé (“Virage”), a company specializing in the manufacturing and marketing of natural health products (“NHPs”), based in Lévis, Quebec. This acquisition increases LSL Pharma’s contract development and manufacturing activities, while creating synergies with its subsidiary LSL Laboratory Inc. (“LSL”). The purchase price of $2.5 million was paid in cash for the acquisition of Virage. The transaction includes an 8,000 sq ft manufacturing plant. The acquisition of Virage will boost LSL Pharma`s revenues by 15-20% annually, as well as broaden...

RENO, Nev., June 18, 2024 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and maker of Battle Born Batteries®, today announced a partnership with Meyer Distributing, a leading distributor of specialty products across North America. Through this collaboration, Dragonfly Energy will leverage Meyer Distributing’s extensive network of over 100 locations across North America to deliver Battle Born Batteries to new business-to-business customers in the recreational vehicle (“RV”) and surrounding industries. “We are thrilled to partner with Meyer Distributing to continue to strengthen our presence within the RV and adjacent markets. We believe this partnership has the potential to empower RV and Overland enthusiasts...

Boston Scientific to acquire Silk Road Medical for $27.50 per share in cash SUNNYVALE, Calif., June 18, 2024 (GLOBE NEWSWIRE) — Silk Road Medical, Inc. (“Silk Road”) (NASDAQ:SILK), a leading minimally invasive medical device company for carotid artery procedures, announced today it has entered into a definitive agreement to be acquired by Boston Scientific Corporation (“Boston Scientific”) (NYSE: BSX), a global medical technology leader, for $27.50 in cash per share, representing an equity value of approximately $1.26 billion. The per share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical’s common stock over the past 60 days. The board of directors of Silk Road has unanimously approved the transaction and recommend that Silk Road stockholders adopt the merger agreement....

After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned Total of 600 Subjects Currently Enrolled in SHIELD II Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in the First Quarter of 2025 PETACH TIKVA, Israel, June 18, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections (SSIs). The Company...

BETHESDA, Md., June 18, 2024 (GLOBE NEWSWIRE) — EagleBank (NASDAQ: EGBN), one of the largest community banks in the Washington, D.C. area, today announced it has onboarded Dan Bostwick and Bob Wallace to lead the Expatriate Banking Services division. This new division aims to meet a strong demand for these services and builds upon EagleBank’s long-term growth strategy, including its recently launched consumer business expansion and digital banking platform. Dan Bostwick and Bob Wallace joined EagleBank with over 20 years of experience each in Expatriate Banking Services. In their roles, they focus on building and strengthening relationships with global corporations and relocation service providers. “As EagleBank continues to enhance and diversify its business model, the Expatriate Banking Services division is an important growth...

SANTA ANA, Calif., June 18, 2024 (GLOBE NEWSWIRE) — Blum Holdings, Inc. (OTCQB: BLMH) (the “Company,” “Blüm Holdings,” “we” or “us”), a cannabis company with subsidiaries operating throughout California, announces a significant milestone in its ongoing strategic financial restructuring. On June 10, 2024, Unrivaled Brands, Inc., a wholly owned subsidiary of Blüm Holdings, completed the sale (the “Disposition”) of its controlling membership interest in People’s First Choice LLC (“PFC”) to Haven Nectar LLC (“Haven Nectar”). PFC owns and operates a cannabis retail dispensary campus in Santa Ana, California named Blüm Santa Ana. Key Highlights of the Disposition The Disposition marks a significant milestone in the Company’s strategic restructuring plan, which began in August 2022. Based on estimates included in the unaudited pro forma...

$10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and seafood production at global scale, potentially tackling significant scalability challenges faced by the cultivated food industryRound led by global corporates with significant equipment, manufacturing, supply chain, and product development experience, alongside a second investment from Tnuva Group, Pluri and additional investors “Ever After Foods’ unique and innovative production platform empowered the change to our business model. The shift to a technology enabler will allow us to serve more players in the value chain,“ said Eyal Rosenthal, Chief Executive Officer of Ever After FoodsHAIFA, Israel, June 18, 2024 (GLOBE NEWSWIRE) — Leading biotechnology company Pluri Inc....